Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Catalent to acquire gummies firm Bettera Holdings for $1B

By Brian Buntz | September 2, 2021

CatalentCatalent (NYSE:CTLT) has been on something of a spending spree during the pandemic.

Looking to bolster its nutraceutical business, the company announced it would acquire Plano, Texas–based Bettera Holdings LLC for $1 billion.

Bettera specializes in gummy, soft chew and lozenge products within nutritional supplements.

Also this year, Catalent has acquired RheinCell Therapeutics, which develops induced pluripotent stem cells (iPSC) technologies and the gene therapy CDMO Delphi Genetics. It has also acquired an additional facility at its Gosselies, Belgium Campus for plasmid DNA manufacturing. In addition, Catalent entered into an agreement with Acorda Therapeutics (NSDQ:ACOR) to purchase a dry-powder inhaler (DPI) capsule manufacturing and packaging facility.

The latest deal will bolster Catalent’s capacity for producing gummy-based vitamins, minerals and supplements. Bettera has four production facilities in the U.S. in California, Indiana, New Jersey and Virginia. It has approximately 500 employees.

“This acquisition is a key strategic move for Catalent’s Consumer Health business, where our leadership in manufacturing technologies and formulation can offer customers more product development opportunities and add manufacturing capacity in this dynamic and fast-growing segment,” said Aris Gennadios, Catalent’s president, softgel and oral technologies, in a statement.

Catalent expects the merger to finalize by the end of the year.

Tell Us What You Think! Cancel reply

Related Articles Read More >

analyzing medical sample
Expert answers to nitrosamine impurity questions
Touchlight
Touchlight inks patent license deal with Pfizer related to the use of dbDNA in mRNA products
Pfizer logo
Pfizer seeks to comply with voluntary Net-Zero Standard by 2040
Cambridge Pharma launches with UK plant in Cambridge Research Park

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards